FDA Approves Two New Antibiotics for Urinary Infections
Patients with complicated infections now have new treatment options available to discuss with their physicians.
Updated on Oct. 26, 2026 in Diseases — General
Live Poll
Do you trust that newer medical treatments are generally safer than older, established options?
The FDA has approved two new antibiotics for treating complicated urinary tract infections, providing new options for patients as of June 2026. These treatments offer alternatives for managing resistant bacterial infections in the United States.
Why it matters
These approvals provide critical new treatment pathways for patients battling resistant infections, especially when traditional options like carbapenems or intravenous drugs are limited. These additions are designed to address specific needs in managing complicated pyelonephritis and infections caused by resistant bacteria.
The Zeus phase three trial established that intravenous fosfomycin is non-inferior to piperacillin-tazobactam for treating complicated urinary tract infections. Oral carbapenem trials, which included participants averaging 65 years of age, compared a four-times-daily regimen against seven days of intravenous imipenem.
The players
FDA
The United States regulatory agency responsible for evaluating the safety and efficacy of new pharmaceutical products.
The details
Intravenous fosfomycin functions by providing an alternative to standard therapies for vancomycin-resistant enterococcus and infections caused by extended-spectrum beta-lactamase-producing Escherichia coli, thereby limiting carbapenem use. The oral carbapenem regimen was specifically optimized to a four-times-daily dose to address reduced performance observed in elderly patients and those with extended-spectrum beta-lactamase-positive pathogens.
Timeline
2022: Trial results indicated oral carbapenem non-inferiority to ertapenem.
October 2025: The FDA granted approval for intravenous fosfomycin.
June 2026: The FDA granted approval for the new oral carbapenem.
Health Landscape
These approvals reflect a broader movement in infectious disease medicine toward diversifying antibiotic strategies to mitigate the rise of resistant bacteria. They represent an evolution from reliance on traditional, broad-spectrum carbapenems toward more targeted, evidence-based antimicrobial regimens.
Patients with complex, recurrent, or resistant urinary tract infections may now have expanded options to discuss with their healthcare providers. Because the intravenous fosfomycin regimen contains six grams of sodium daily, individuals managing cardiovascular health or fluid restrictions should review this factor with their physician.
The takeaway
These new antibiotics offer critical tools for managing complex infections when standard therapies fall short. When navigating treatment options for recurrent or resistant infections, always have a detailed conversation with your physician regarding potential side effects and your individual health history.
Further reading
For more information on the management of bacterial infections, visit Diseases — General.
Source note: This article includes information reported by Ajmc.
Live Poll
Do you trust that newer medical treatments are generally safer than older, established options?
